Company / Revenue
Abbott Laboratories Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$44.3B
FY2025
5-year range
$31.9B / $44.3B
FY2021-FY2025
Trend
+5.7%
vs FY2024
Sector context
#12 of 156
Health Care
What the data says
Among 156 Health Care companies, Abbott Laboratories is in the top 8% for revenue. Revenue has fluctuated over the past 10 years, ranging from $20.2B in FY2016 to $44.3B in FY2025.
Based on SEC 10-K filings.
$44.3B in FY2025 with a 5-year CAGR of +7.7%. Top quartile in the Health Care sector.
Improved from $43.1B to $44.3B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +7.7%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 156This company $44.3B Sector average $19.0B
▼
+133.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.7%, indicating consistent growth.
- In FY2025, revenue increased 5.7% year-over-year.
- Ranks #12 out of 156 companies in the Health Care sector.
- Lowest revenue in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.3B | +5.7% |
| FY2024 | $42.0B | -2.6% |
| FY2023 | $43.1B | +24.5% |
| FY2022 | $34.6B | +8.5% |
| FY2021 | $31.9B | +4.3% |
| FY2020 | $30.6B | -4.2% |
| FY2019 | $31.9B | +53.0% |
| FY2018 | $20.9B | +2.2% |
| FY2017 | $20.4B | +0.8% |
| FY2016 | $20.2B | +3.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026